Praxis reports positive elsunersen trial in pediatric epilepsies

The latest announcement is out from Praxis Precision Medicines ( (PRAX) ).

Praxis Precision Medicines reported positive topline results from its EMBRAVE Part A Phase 1/2 trial of elsunersen in pediatric patients aged 2 to 12 years with early-onset SCN2A developmental and epileptic encephalopathy, a rare and severe seizure disorder. The study, which used a randomized, placebo-controlled design followed by an open-label extension, showed a 77% placebo-adjusted seizure reduction from baseline, seizure-free periods in 57% of treated patients, sustained efficacy for up to one year, and improvements in sleep, motor function, muscle tone, attention or neuropsychomotor development, with elsunersen well-tolerated and no drug-related serious adverse events.

The company also disclosed that the U.S. Food and Drug Administration has accepted its New Drug Application for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies and granted it priority review, with a target action date of September 27, 2026. These developments collectively underscore Praxis’s advancing pipeline in rare pediatric epilepsies and may strengthen its position in the emerging market for targeted therapies addressing genetically defined seizure disorders.

The most recent analyst rating on (PRAX) stock is a Buy with a $510.00 price target. To see the full list of analyst forecasts on Praxis Precision Medicines stock, see the PRAX Stock Forecast page.

Spark’s Take on PRAX Stock

According to Spark, TipRanks’ AI Analyst, PRAX is a Neutral.

The score is supported most by strong technical momentum and a positive earnings-call setup (NDA filings, Breakthrough designation, multiple near-term catalysts, and an extended cash runway). These are tempered by weak underlying financial performance (no revenue in 2025, widening losses, and significant cash burn) and limited valuation support due to negative earnings and no dividend.

To see Spark’s full report on PRAX stock, click here.

More about Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on developing treatments for rare, genetically driven epileptic encephalopathies, including SCN2A and SCN8A developmental and epileptic encephalopathies. The company’s pipeline includes small molecules and other targeted therapies aimed at severe pediatric seizure disorders with significant unmet medical need.

Average Trading Volume: 494,439

Technical Sentiment Signal: Buy

Current Market Cap: $8.64B

Find detailed analytics on PRAX stock on TipRanks’ Stock Analysis page.